New UK research illuminates new developments for anticancer treatment
October 26, 2016Research and Development anticancer
New research from the University of Huddersfield has shed light on a new lab technique which could aid in the …
MSD’s Keytruda given first FDA approval for first line treatment
October 25, 2016Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo
MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …
Novartis rides out fiscal hardship to beat Q3 forecasts
October 25, 2016Manufacturing and Production, Sales and Marketing Entresto, Gleevec, Novartis
Novartis has beaten its third-quarter sales projections, announcing that new product growth and cost cuts managed to carry the company …
Dr Reddy’s Laboratories profits drop 60%
October 25, 2016Manufacturing and Production, Sales and Marketing Dr Reddy's Laboratories
Indian pharmaceutical firm Dr Reddy’s Laboratories has suffered a drop of 60.12% in consolidated net profit for the September quarter. …
EMA opens clinical trial data to public
October 25, 2016Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials
The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …
Concordia founder resigns and will step down once replacement found
October 25, 2016Manufacturing and Production CEO, Concordia, Mark Thompson, Valeant
Concordia International Corp., the Ontario-based company, has announced that its founder, Chairman and Chief Executive Officer, Mark Thompson, will leave …
Colombian pharma market to break $7 billion by 2020
October 24, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Colombia, market report
According to new findings from GlobalData, the Colombian pharmaceutical market is due to grow from $5 billion in 2015 to …
FDA accepts another Opdivo indication for priority review
October 24, 2016Sales and Marketing BMS, Bristol-Myers Squibb, FDA, opdivo
The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …
MSD’s Keytruda early success ends trial early
October 24, 2016Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq
MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
Phase III depression trial success for Alkermes
October 24, 2016Research and Development, Sales and Marketing ALKS 5461, Alkermes, major depressive disorder
Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …
GSK applies for FDA approval for shingles vaccine
October 24, 2016Sales and Marketing GSK, GlaxoSmithKline, Vaccine, chickenpox, shingles
GlaxoSmithKlien, the UK’s biggest drugmaker, is seeking approval from the FDA for a shingles (herpes zoster) vaccine. The vaccine would …
Top Ten articles in the pharma industry this week
October 21, 2016Medical Communications biggest stories, news, week, weekly
This week has seen a few big collaboration and partnerships occur, whilst there have been some major movements within immunotherapy …
Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment
October 21, 2016Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer
Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …
Gilead’s drug boosted by positive Phase II trials and aims to move forward
October 21, 2016Medical Communications Gilead, Gilead Sciences, clinical trials, fatty liver disease
Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …
UK Government announces deep cuts to pharmacy funding
October 21, 2016Medical Communications Conservative, NHS, UK, government, pharmacy
The Department Health announced that it wanted to reduce the £2.8 billion a year funding for pharmacies by 7%, leading …
FDA advisory committee approves of Allergan’s night-time urination medicine
October 20, 2016Medical Communications Allergan, FDA, Night-time urination, sleep, urination
The FDA’s advisory committee ruled, in a 14-4 vote, that Allergan’s experimental nocturnal urination medication, SER120, in favour of the …
Eli Lilly gains accelerated approval from FDA for soft tissue sarcoma drug
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, US, soft tissue sarcoma
Eli Lilly received the positive news that their drug, Lartruvo, has been granted accelerated approval for use in conjunction with …
The Pharmafocus guide to the US presidential election 2016
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing US election, feature
The US presidential election is mere weeks away, and the pharmaceutical industry and drug pricing have occupied quite a large …
Novartis in collaboration deal worth potential $1.2 billion with Cerulean
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerulean, NDC, Novartis
Novartis has signed an agreement with Cerulean Pharma, worth a potential $1.2 billion depending on milestones met, to co-develop nanoparticle-drug …
Celgene’s Otezla approved by NICE for chronic plaque psoriasis
October 20, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, NICE, apremilast, otezla
NICE has given its approval to another indication for Celgene’s Otezla (apremilast), meaning NHS patients now have access to the …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
